SWK-002

N/A

Report date: 2024/09/12 16:15:42

Base Information

Drug NameSWK-002
Drug Alias NameSWK002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesThe First Affiliated Hospital Of University Of Science And Technology Of China
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of University Of Science And Technology Of China
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A